# MP Healthcare Venture Management

> MP Healthcare Venture Management is a VC fund backing Biotechnology. See 48 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 48
- Last investment: Jun 2026
- Lead investor: 10%
- Last updated: Aug 2026
- Website: http://www.mp-healthcare.com

MP Healthcare Venture Management is a VC fund in Boston focused on Biotechnology and Health Care. MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corporation (MTPC). MPH invests in innovative companies developing novel therapeutics, platform technologies, and vaccines.

## Contacts

5 contacts available for MP Healthcare Venture Management. Shizune tracks 1 team members at MP Healthcare Venture Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mp-healthcare-venture-management-inc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 26 | 54% |
| Health Care | 13 | 27% |
| Therapeutics | 11 | 23% |
| Pharmaceutical | 7 | 15% |
| Medical | 6 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 11 | 23% |
| Series B | 10 | 21% |
| Series A | 8 | 17% |
| Series C | 5 | 10% |
| Funding Round | 3 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 27% |
| Switzerland | 3 | 6% |
| United Kingdom | 3 | 6% |
| Canada | 2 | 4% |
| Italy | 1 | 2% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeffrey Moore | President & Board Member | 6 | https://shizune.co/investors/profile/jeffrey-moore-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M | Series B | May 27, 2025 |  |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M | Seed | Mar 05, 2025 |  |
| Libero Thera | LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $1.3M | Venture - Series Unknown | Aug 01, 2024 |  |
| Draupnir Bio | Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company isable to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases. | $13.2M | Seed | Jul 17, 2024 |  |
| Outrun TX | Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway. | $10M | Seed | Apr 18, 2024 |  |
| PharmEnable | PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M | Seed | May 22, 2023 |  |
| PharmEnable | PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M | Seed | May 22, 2023 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M | Series B | Mar 09, 2023 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $116M | Series B | Jan 05, 2022 |  |

10 of 48 investments shown.

## Co-investors
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 8 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 7 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 5 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 4 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 4 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)

## FAQ

### What does MP Healthcare Venture Management invest in?

MP Healthcare Venture Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series B stage. Most of the 48 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact MP Healthcare Venture Management?

Public channels for MP Healthcare Venture Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at MP Healthcare Venture Management?

The team at MP Healthcare Venture Management includes Jeffrey Moore (President & Board Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co